COMPARED TO INSULIN GLARGINE, TIRZEPATIDE REDUCES THE PREVALENCE OF THE METABOLIC SYNDROME IN PATIENTS WITH TYPE 2 DIABETES AND HIGH CARDIOVASCULAR RISK: POST-HOC ANALYSIS OF SURPASS-4

被引：0
|
作者：
Nicholls, Stephen J. [1 ]
D'Alessio, David [1 ]
Wiese, Russell [1 ]
Pavo, Imre [1 ]
Zeytinoglu, Meltem [1 ]
Romera, Irene [1 ]
Weerakkody, Govinda J. [1 ]
机构：
[1] Eli Lilly & Co, Indianapolis, IN USA
来源：
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY | 2023年 / 81卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
910-10
引用
收藏
页码：1628 / 1628
页数：1
相关论文
共 50 条
  • [1] Tirzepatide Reduces High-Sensitivity C-reactive Protein in Patients With Type 2 Diabetes and High Cardiovascular Risk: A Post Hoc Analysis of the SURPASS-4 Trial
    Bhatt, Deepak L.
    Wilson, Jonathan M.
    Wiese, Russell J.
    Yang, Zhengyu
    Duffin, Kevin L.
    Pavo, Imre
    CIRCULATION, 2023, 148
  • [2] Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial
    Heerspink, Hiddo J. L.
    Sattar, Naveed
    Pavo, Imre
    Haupt, Axel
    Duffin, Kevin L.
    Yang, Zhengyu
    Wiese, Russell J.
    Tuttle, Katherine R.
    Cherney, David Z. I.
    LANCET DIABETES & ENDOCRINOLOGY, 2022, 10 (11): : 774 - 785
  • [3] Tirzepatide reduces albuminuria in patients with type 2 diabetes: post-hoc pooled analysis of SURPASS 1-5
    Wiese, R. J.
    Heerspink, H. J. L.
    Tuttle, K. R.
    Pavo, I.
    Haupt, A.
    Yang, Z.
    Hemmingway, A.
    Cherney, D. Z. I.
    Sattar, N.
    DIABETOLOGIA, 2023, 66 (SUPPL 1) : S4 - S4
  • [4] Sustainability of HbA1c control of tirzepatide vs insulin glargine in people with type 2 diabetes and increased cardiovascular risk: SURPASS-4
    Kahn, S. E.
    Del Prato, S.
    Pavo, I.
    Franco, D. R.
    Yang, Z.
    Wiese, R. J.
    Pearson, E. R.
    DIABETOLOGIA, 2022, 65 (SUPPL 1) : S284 - S284
  • [5] Effects of Tirzepatide Versus Insulin Glargine on Cystatin C-Based Kidney Function: A SURPASS-4 Post Hoc Analysis
    Heerspink, Hiddo J. L.
    Sattar, Naveed
    Pavo, Imre
    Haupt, Axel
    Duffin, Kevin L.
    Yang, Zhengyu
    Wiese, Russell J.
    Wilson, Jonathan M.
    Hemmingway, Andrea
    Cherney, David Z. I.
    Tuttle, Katherine R.
    DIABETES CARE, 2023, 46 (08) : 1501 - 1506
  • [6] Sustainability of HbA1c Control of Tirzepatide vs. Insulin Glargine in People with Type 2 Diabetes and Increased Cardiovascular Risk (SURPASS-4)
    Pearson, Ewan
    Del Prato, Stefano
    Pavo, Imre
    Franco, Denise R.
    Yang, Zhengyu
    Wiese, Russell
    Kahn, Steven E.
    DIABETES, 2022, 71
  • [7] Tirzepatide reduces serum triglyceride concentrations irrespective of concomitant fibrate use in SURPASS-4 participants with type 2 diabetes at high cardiovascular risk
    Varkonyi, T.
    Del Prato, S.
    Pavo, I.
    Nicolay, C.
    Wiese, R. J.
    Kahn, S. E.
    DIABETOLOGIA, 2022, 65 (SUPPL 1) : S305 - S305
  • [8] Effects of tirzepatide versus insulin glargine 100 U/mL on kidney outcomes in participants with type 2 diabetes in SURPASS-4
    Heerspink, H. J. L.
    Sattar, N.
    Pavo, I.
    Haupt, A.
    Duffin, K. L.
    Yang, Z.
    Wiese, R. J.
    Tuttle, K. R.
    Cherney, D. Z. I.
    DIABETOLOGIA, 2022, 65 (SUPPL 1) : S316 - S316
  • [9] Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial
    Del Prato, Stefano
    Kahn, Steven E.
    Pavo, Imre
    Weerakkody, Govinda J.
    Yang, Zhengyu
    Doupis, John
    Aizenberg, Diego
    Wynne, Alan G.
    Riesmeyer, Jeffrey S.
    Heine, Robert J.
    Wiese, Russell J.
    LANCET, 2021, 398 (10313): : 1811 - 1824
  • [10] Patient-Reported Outcomes in Patients with T2D and increased CV risk on Tirzepatide or Insulin Glargine (SURPASS-4)
    Boye, K. S.
    Pavo, I.
    Wiese, R. J.
    Yang, Z.
    Weerakkody, G. J.
    Lando, L. Fernandez
    Yu, M.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2022, 186
12345